Cell Therapies for Regenerative Medicine
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
829
NCT06561425
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 9, 2022
Completion: Jul 1, 2029
NCT05947578
The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.
Phase: Phase 1
Start: Jun 19, 2023
Completion: Aug 9, 2024
NCT06652633
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Phase: Phase 3
Start: Sep 9, 2024
Completion: Jul 31, 2039
Loading map...